Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating patients with hemophilia A or B with inhibitors met its primary endpoint as ...

Discover how hemophilia A affects blood clotting, its genetic patterns, warning signs, advanced treatment options, and lifestyle modifications ...

People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of ...

Pfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and adolescents living with hemophilia A or B with inhibitors in a late-stage ...

Gene therapy for hemophilia is highly expensive, although proponents noted that insurers may save money over the long run if patients don’t require prophylactic treatment or therapy for bleeds.

The FDA has approved Alhemo® to prevent or reduce bleeding episodes in patients 12 years and older with hemophilia A or B with inhibitors.

Pfizer has decided to discontinue its hemophilia B gene therapy Beqvez, leaving no active gene therapy program in the company's portfolio.

Pfizer’s hemophilia A gene therapy reduced annualized bleeding rates in a Phase 3 clinical trial, setting the stage for discussions with regulators. However, the market for such one-time ...

BUFFALO, N.Y. – University at Buffalo researcher Sathy Balu-Iyer has been awarded a three-year, $1.5 million grant to continue his work on enabling a patient’s immune system to accept treatment for ...

Certain immune markers in the blood may help predict ITI response among hemophilia A patients given immune tolerance induction, a study found.

Hemlibra safely reduces bleeding episodes in people with hemophilia A without inhibitors, per a review study that confirmed ...